The analyst rating for FOSUN INTL (00656.HK) is maintained as a Buy by Citi, despite the lowered target price from HKD6.5 to HKD5.6. The reason for this rating is based on the profit warning issued by its subsidiary, Shanghai Yuyuan, which is expected to record a significant net loss of RMB4.8 billion for FY25. Additionally, Citi's forecasts for FOSUN INTL's other businesses, particularly in the health sector, suggest a net loss of around RMB778 million for FY25. Despite these challenges, the Buy rating indicates that Citi believes there is still potential for recovery or value in the stock.
